Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
group_3_presentation_2_-_lsd_s_lysergic_acid_diethylamide_effect_on_the_brain [2017/11/03 03:14] hamidy2 [Research / Applications] |
group_3_presentation_2_-_lsd_s_lysergic_acid_diethylamide_effect_on_the_brain [2018/01/25 15:18] (current) |
||
|---|---|---|---|
| Line 181: | Line 181: | ||
| Aghajanian, G. K., & Marek, G. J. (1999). Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. //Brain Research, 825(1–2)//, 161–171. https://doi.org/10.1016/S0006-8993 | Aghajanian, G. K., & Marek, G. J. (1999). Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. //Brain Research, 825(1–2)//, 161–171. https://doi.org/10.1016/S0006-8993 | ||
| - | **Blachford, S. L., & Krapp, K. (2010). LSD (lysergic acid diethylamide). Drugs and Controlled Substances: Information for Students. Detroit: Gale. Retrieved from http://sproxy.glenbrook225.org/login?url=http://link.galegroup.com/apps/doc/CV2645000028/SCIC?u=gotitans&xid=8a0a151 - Incorrect Format** | + | Blachford, S. L., & Krapp, K. (2010). LSD (lysergic acid diethylamide). Drugs and Controlled Substances: Information for Students. Retrieved from http://sproxy.glenbrook225.org/login?url=http://link.galegroup.com/apps/doc/CV2645000028/SCIC?u=gotitans&xid=8a0a151 |
| Blewett D., and Chwelos N. (1959). //Handbook for the therapeutic use of lysergic acid diethylamide 25 individual and group procedures.// Retrieved from https://www.erowid.org/psychoactives/guides/handbook_lsd25.shtml | Blewett D., and Chwelos N. (1959). //Handbook for the therapeutic use of lysergic acid diethylamide 25 individual and group procedures.// Retrieved from https://www.erowid.org/psychoactives/guides/handbook_lsd25.shtml | ||
| Line 196: | Line 196: | ||
| Grinspoon L., & Bakalar J. (1997). //Psychedelic Drugs Reconsidered//. New York, NY, USA: Lindesmith Center. | Grinspoon L., & Bakalar J. (1997). //Psychedelic Drugs Reconsidered//. New York, NY, USA: Lindesmith Center. | ||
| - | |||
| - | **Grob C. (2002). Conversation with Albert Hofmann. In: Grob C., editor. (ed.), Hallucinogens: A Reader. New York: Tarcher/Putnam, pp. 15–22. - Incorrect Form** | ||
| Hermann, E. (2016). //What You Should Know About Quitting LSD//. Retrieved from https://www.recovery.org/topics/quitting-lsd/ | Hermann, E. (2016). //What You Should Know About Quitting LSD//. Retrieved from https://www.recovery.org/topics/quitting-lsd/ | ||
